Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 May;131(5):E1558-E1566.
doi: 10.1002/lary.29206. Epub 2020 Oct 24.

Management of Head and Neck Cancers With or Without Comorbid HIV Infection in Botswana

Affiliations
Observational Study

Management of Head and Neck Cancers With or Without Comorbid HIV Infection in Botswana

Gwendolyn J McGinnis et al. Laryngoscope. 2021 May.

Abstract

Objectives/hypothesis: Head and neck cancer (HNC) is the fifth most common malignancy in sub-Saharan Africa, a region with hyperendemic human immunodeficiency virus (HIV)-infection. HIV patients have higher rates of HNC, yet the effect of HIV-infection on oncologic outcomes and treatment toxicity is poorly characterized.

Study design: Prospective observational cohort study.

Methods: HNC patients attending a government-funded oncology clinic in Botswana were prospectively enrolled in an observational cohort registry from 2015 to 2019. Clinical characteristics were analyzed via Cox proportional hazards and logistic regression followed by secondary analysis by HIV-status. Overall survival (OS) was evaluated via Kaplan-Meier.

Results: The study enrolled 149 patients with a median follow-up of 23 months. Patients presented with advanced disease (60% with T4-primaries), received limited treatment (19% chemotherapy, 8% surgery, 29% definitive radiation [RT]), and had delayed care (median time from diagnosis to RT of 2.5 months). Median OS was 36.2 months. Anemia was associated with worse survival (HR 2.74, P = .001). Grade ≥ 3 toxicity rate with RT was 30% and associated with mucosal subsite (OR 4.04, P = .03) and BMI < 20 kg/m2 (OR 6.04, P = .012). Forty percent of patients (n = 59) were HIV-infected; most (85%) were on antiretroviral therapy, had suppressed viral loads (90% with ≤400 copies/mL), and had immunocompetent CD4 counts (median 400 cells/mm3 ). HIV-status was not associated with decreased receipt or delays of definitive RT, worse survival, or increased toxicity.

Conclusions: Despite access to government-funded care, HNC patients in Botswana present late and have delays in care, which likely contributes to suboptimal survival outcomes. While a disproportionate number has comorbid HIV infection, HIV-status does not adversely affect outcomes.

Level of evidence: 2c Laryngoscope, 131:E1558-E1566, 2021.

Keywords: Global oncology; HIV-related neoplasms; HPV-related malignancies; Head and neck neoplasms; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

AL has no conflicts of interest regarding the material in this manuscript, but does report being on an advisory board for Ion Beam applications (paid honorarium) and conducting education for Provision Healthcare (paid honorarium).

The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Figures

Fig. 1.
Fig. 1.
Survival outcomes of head-and-neck cancer patients in Botswana by radiation therapy intent: no radiation (n = 48), non-definitive RT (n = 58), and definitive RT (n = 43).a Abbreviations: RT, radiation therapy; Path, pathological.
Fig. 2.
Fig. 2.
Survival outcomes by HIV status: infected (n = 59) versus uninfected (n = 90).

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
    1. Ferlay J, Ervik M, Lam F, et al. Cancer today. Global cancer observatory. Accessed January 26, 2020. https://gco.iarc.fr/today
    1. Brown CA, Suneja G, Tapela N, et al. Predictors of timely access of oncology services and advanced-stage cancer in an HIV-endemic setting. Oncologist 2016;21:731–738. - PMC - PubMed
    1. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. Lancet Oncol 2015;16:1153–1186. - PubMed
    1. Fidler MM, Bray F, Soerjomataram I. The global cancer burden and human development: a review. Scand J Public Health 2018;46:27–36. - PubMed

Publication types

MeSH terms

Substances